Third Rock Ventures sells shares in Tango Therapeutics worth over $700k

Investors following Tango Therapeutics, Inc. (NASDAQ:TNGX) may be interested to learn that Third Rock Ventures IV, L.P., a significant shareholder in the company, has recently sold a portion of its holdings. The transaction, which took place on September 13, 2024, involved the sale of 67,400 shares of common stock at a weighted average price of $10.5305 per share, totaling approximately $709,755.


The shares were sold in multiple transactions with prices ranging from $10.50 to $10.74. This range of prices indicates a level of activity in the stock around that valuation period. Following the sale, Third Rock Ventures IV, L.P. still holds a substantial amount of Tango Therapeutics' shares, with 16,859,075 shares remaining in their possession.


The ownership structure behind these transactions is layered. Third Rock Ventures IV, L.P. is directly holding the shares, with Third Rock Ventures GP IV, L.P. being the general partner, and TRV GP IV, LLC acting as the general partner of Third Rock Ventures GP IV, L.P. Kevin Gillis, the Chief Operating Officer of TRV GP IV, LLC, signed off on the transactions.


For those tracking insider transactions as an indicator of corporate confidence, it's important to note that none of the reporting owners are listed as officers or directors of Tango Therapeutics, but they are acknowledged as ten percent owners, indicating a significant investment in the company.


Tango Therapeutics, headquartered in Boston, MA, is a biotechnology company focused on developing treatments in the pharmaceutical preparations sector. The sale by Third Rock Ventures is part of the normal course of investment management and does not necessarily indicate a lack of confidence in the company’s future prospects.


Investors and security holders of Tango Therapeutics can request more detailed information about the sale transactions from the reporting person if needed.



In other recent news, Tango Therapeutics continues to make strides in its drug development pipeline. Piper Sandler maintained its Overweight rating on Tango Therapeutics, emphasizing the potential of the company's PRMT5 inhibitors, TNG462 and TNG908. The firm's stance is backed by preclinical data and early clinical experiences, suggesting these programs may demonstrate compelling early clinical profiles. Initial data from Tango Therapeutics' trials are expected by the end of 2024.


Analysts from H.C. Wainwright also maintained a Buy rating on shares of Tango Therapeutics, with a consistent price target of $13.00. This followed the release of updated results for AMG 193, a PRMT5 inhibitor that is relevant to the evaluation of Tango Therapeutics' prospects. Furthermore, Jefferies issued a Buy rating and a price target of $19.00, focusing on the potential of Tango's lead assets, '908 and '462. They anticipate a significant data update for both programs in the second half of 2024.


However, Tango Therapeutics recently halted development of its key drug candidate, TNG348, due to observed liver function abnormalities in trial participants. Despite this setback, the company's cash runway is now projected to last into 2027, allowing the company to explore other therapeutic opportunities, particularly the PRMT5 program. These are the latest developments in Tango Therapeutics' commitment to advancing its portfolio and ensuring its clinical programs stay on track.
InvestingPro Insights


Amid the recent insider transactions at Tango Therapeutics, Inc. (NASDAQ:TNGX), investors may benefit from a closer look at the company's financial health and market performance. Tango Therapeutics has a market capitalization of $923.59 million, which positions it as a mid-cap company in the biotechnology sector. Notably, the company holds more cash than debt on its balance sheet, which is a positive sign for investors concerned about financial stability.


Analyzing the company's profitability, Tango Therapeutics has not been profitable over the last twelve months, and analysts do not anticipate the company will be profitable this year. This is further reflected in the company's negative gross profit margin of -218.07% for the same period. Such metrics suggest that Tango Therapeutics is facing challenges in maintaining profitability and cost efficiency, which could be significant for investors considering the stock's future prospects.


Despite these challenges, Tango Therapeutics' liquid assets exceed its short-term obligations, indicating a sound liquidity position that may reassure investors about the company's ability to meet its short-term financial commitments. Nevertheless, it's worth noting that five analysts have revised their earnings downwards for the upcoming period, signaling potential headwinds that could impact the company's performance.


For those interested in further analysis, InvestingPro offers additional insights and metrics on Tango Therapeutics. Currently, there are seven more InvestingPro Tips available for TNGX at https://www.investing.com/pro/TNGX, providing a comprehensive overview for investors seeking to understand the company's financial nuances in greater detail.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com